摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tris-(hydroxymethyl)methylammonium-2-(2,6-dichloroanilino)phenylacetate | 86522-09-0

中文名称
——
中文别名
——
英文名称
tris-(hydroxymethyl)methylammonium-2-(2,6-dichloroanilino)phenylacetate
英文别名
2-[2-(2,6-Dichloroanilino)phenyl]acetate;tris(hydroxymethyl)-methylazanium
tris-(hydroxymethyl)methylammonium-2-(2,6-dichloroanilino)phenylacetate化学式
CAS
86522-09-0
化学式
C4H12NO3*C14H10Cl2NO2
mdl
——
分子量
417.289
InChiKey
NJTLAOVYRDBVEY-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.31
  • 重原子数:
    27
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    113
  • 氢给体数:
    4
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Pharmaceutical preparations for topical application which contain salts
    申请人:Ciba-Geigy Corporation
    公开号:US04407824A1
    公开(公告)日:1983-10-04
    The invention relates to pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids, in particular compounds of the formula ##STR1## wherein R.sub.1 is a group of the formula ##STR2## wherein X.sub.1 and X.sub.2 are hydrogen and X.sub.3 is isobutyl, or X.sub.1 and X.sub.3 are hydrogen and X.sub.2 is benzoyl, or X.sub.1 is hydrogen, X.sub.2 is chlorine, and X.sub.3 is 3-pyrrolin-1-yl, or X.sub.1 is hydrogen, X.sub.2 is a group of the formula --CH.dbd.CH--C(OCH.sub.3).dbd.CH--X.sub.4, and X.sub.3 together with X.sub.4 are a bond, and R.sub.2 is methyl, or X.sub.2 and X.sub.3 are hydrogen and X.sub.1 is 2,6-dichloroanilino, and R.sub.2 is hydrogen, or R.sub.1 is a group of the formula ##STR3## wherein X.sub.5 is the common bond with the methine group in formula I, X.sub.6 and X.sub.7 are hydrogen, X.sub.8 is p-methylbenzoyl, Y is a nitrogen atom, and X.sub.9 is a methyl group, or X.sub.5 is a methyl group, X.sub.6 is a common bond with the methine group in formula I, X.sub.7 is a group of the formula --CH.dbd.C(OCH.sub.3)--CH.dbd.CH--X.sub.10, X.sub.8 together with X.sub.10 are a bond, Y is a nitrogen atom and X.sub.9 is p-chlorobenzoyl, or X.sub.5 is a methyl group, X.sub.6 is the common bond with the methine group in formula I, X.sub.7 is a group of the formula --CH.dbd.C(F)--CH.dbd.CH--X.sub.11, X.sub.8 together with X.sub.11 are a bond, Y is a carbon atom and X.sub.9 is (p-methanesulfinylphenyl)methylene, and R.sub.2 is hydrogen, and each of R.sub.3, R.sub.4 and R.sub.5 independently is hydrogen, an aliphatic radical, or two of R.sub.3, R.sub.4 and R.sub.5 together are a bivalent aliphatic radical, unsubstituted or substituted or interrupted by aza, oxa or thia, with the proviso that at least one of R.sub.3, R.sub.4 and R.sub.5 is different from hydrogen, optionally in the form of an isomer, together with conventional carriers and/or excipients for topical application. The invention also relates to the production of these preparations and also to novel compounds of the formula I and a process for their production. The compounds of the formula I are suitable for use as anti-inflammatory agents and/or analgesics for topical application.
    该发明涉及用于局部应用的药物制剂,其包含烷基羧酸盐,特别是具有以下结构的化合物:其中R.sub.1是以下结构的基团:其中X.sub.1和X.sub.2是氢,X.sub.3是异丁基;或者X.sub.1和X.sub.3是氢,X.sub.2是苯甲酰基;或者X.sub.1是氢,X.sub.2是氯,X.sub.3是3-吡咯烯-1-基;或者X.sub.1是氢,X.sub.2是--CH.dbd.CH--C(OCH.sub.3).dbd.CH--X.sub.4结构基团,X.sub.3和X.sub.4是键合;R.sub.2是甲基;或者X.sub.2和X.sub.3是氢,X.sub.1是2,6-二氯苯胺基,R.sub.2是氢;或者R.sub.1是以下结构的基团:其中X.sub.5是与式I中的甲烯基团共价键,X.sub.6和X.sub.7是氢,X.sub.8是对甲苯甲酰基,Y是氮原子,X.sub.9是甲基;或者X.sub.5是甲基,X.sub.6是与式I中的甲烯基团共价键,X.sub.7是--CH.dbd.C(OCH.sub.3)--CH.dbd.CH--X.sub.10结构基团,X.sub.8和X.sub.10是键合,Y是氮原子,X.sub.9是对氯苯甲酰基;或者X.sub.5是甲基,X.sub.6是与式I中的甲烯基团共价键,X.sub.7是--CH.dbd.C(F)--CH.dbd.CH--X.sub.11结构基团,X.sub.8和X.sub.11是键合,Y是碳原子,X.sub.9是(p-甲烷磺酰基苯基)甲烯基,R.sub.2是氢,且R.sub.3、R.sub.4和R.sub.5中的每一个独立地是氢、脂肪基,或者R.sub.3、R.sub.4和R.sub.5中的两个共同构成双价脂肪基,未经取代或被氮、氧或硫替代或中断,但要求R.sub.3、R.sub.4和R.sub.5中至少一个与氢不同,可选地以异构体的形式存在,同时含有用于局部应用的常规载体和/或赋形剂。该发明还涉及这些制剂的生产以及公式I的新化合物,以及其生产工艺。公式I的化合物适用于作为局部应用的抗炎药和/或止痛药。
  • ——
    作者:
    DOI:——
    日期:——
  • US4407824A
    申请人:——
    公开号:US4407824A
    公开(公告)日:1983-10-04
  • US4551475A
    申请人:——
    公开号:US4551475A
    公开(公告)日:1985-11-05
  • US4619926A
    申请人:——
    公开号:US4619926A
    公开(公告)日:1986-10-28
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐